Drug Profile
BYK 321084
Alternative Names: BYK321084; PDE4 inhibitor - Nycomed; PDE4 inhibitor – Takeda; PDE4i – Nycomed; TAK-084; Type 4 cyclic nucleotide phosphodiesterase inhibitor – NycomedLatest Information Update: 29 Apr 2016
Price :
$50
*
At a glance
- Originator Nycomed
- Developer Takeda Pharmaceuticals International GmbH
- Class Anti-inflammatories; Antipsoriatics; Phenanthridines; Skin disorder therapies
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammation; Plaque psoriasis
Most Recent Events
- 29 Apr 2016 No recent reports on development identified - Phase-I for Inflammation in Europe (Topical)
- 29 Apr 2016 No recent reports on development identified - Phase-I for Plaque psoriasis in Germany (Topical)
- 29 Apr 2016 Primary efficacy data from a phase I trial in Plaque psoriasis released by Takeda